Astellas, MMV partner to identify antimalarial compounds

Astellas Pharma Inc. (Tokyo:4503) and Medicines for Malaria Venture (Geneva, Switzerland) partnered to identify antimalarial candidates. MMV will work with Vicky Avery, a professor at Griffiths University (Brisbane, Australia), to screen Astellas’ library for compounds that demonstrate the potential to become new antimalarial drugs...